EU MDR – Person Responsible for Regulatory Compliance (PRRC)
The EU Medical Devices Regulation (MDR) lays down the rules regarding the placing on the market, making available on the market or putting into service of medical devices and accessories for such devices. When compared to the prior applicable Directives, the MDR (and also IVDR) makes it mandatory for manufacturers to have within their organizations at least one Person Responsible for Regulatory Compliance.

MDR, IVDR AND PRRC

In 2017, two Regulations on medical devices and in in vitro diagnostic medical devices entered into force in the European Union (EU), progressively replacing the 3 existing Directives. The main goal was to establish a modernized and more robust EU legislative framework and to safeguard a better public health protection and patient safety.

The EU Medical Devices Regulation (MDR – Regulation (EU) 2017/745) lays down the rules regarding the placing on the market, making available on the market or putting into service of medical devices for human use (and accessories for such devices). The Regulation (EU) 2017/746 sets out the rules on in vitro diagnostic medical devices (IVDR).

According to Article 15 of both Regulations, it is mandatory for manufacturers to have, within their organization (as an employee), a person responsible for regulatory compliance (PRRC). Importers and Authorized Representatives must also have an PRRC. The PRRC must possess requisite expertise in the field of medical devices, which shall be demonstrated with one of the following qualifications:

  • Four years of professional experience in regulatory affairs or in quality management systems relating to medical devices;
  • Diploma, certificate (or other formal qualification) from a university degree in law, medicine, pharmacy, engineering or other relevant scientific discipline (recognized as equivalent by the Member State concerned) and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices.

If the qualification was obtained outside the EU it must be recognized by an EU Member State as equivalent to the EU corresponding qualification. The professional experience should be related to the EU requirements in the field.

The PRRC is responsible for the technical documentation, EU Declaration of Conformity (drawn up and kept up-to-date), post-market surveillance obligations and checking the conformity of devices before they are released (according to the quality management system implemented). Vigilance activities, recording and reporting incidents, safety and performance requirements, clinical investigations and performance studies are also among the responsibilities and roles of the PRRC.

Each legal manufacturer must have its own PRRC. The PRRC must be close to the manufacturer, which means that if the manufacturer is located in the EU, its PRRC must also be located in the EU.

When it comes to micro and small manufacturers, they may subcontract the responsibilities of a PRRC to a third party, but it must be available permanently and continuously to them. This is also the case for Authorized Representatives, who may also outsource this role. The PRRC of an Authorized Representative (AR) is responsible for ensuring that the tasks of the AR (as specified in the given mandate) are fulfilled.

An AR and a manufacturer established outside the EU cannot have the same PRRC, ensuring a higher level of scrutiny and that the supervision and control of the production of devices, post-market surveillance and vigilance activities are effectively performed. For the same purpose, the PRRC of a micro and small manufacturer and the PRRC of the AR of that same company shall not belong to the same external organization.

References:

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices.
  2. Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices.
  3. MDCG 2019-7 – Guidance on Article 15 of the Medical Device Regulation (MDR) and in vitro Diagnostic Device Regulation (IVDR) regarding a “person responsible for regulatory compliance” (PRRC).

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »